J. Sagar Associates (JSA) advised and assisted Omidyar Network (ON) (Mauritius) in connection with its Series B1 round investment in Advamedica Inc (Advamedica). ON led the investment round, which also saw participation from existing investors of Advamedica.
ON is a US based investment firm which focuses on social impact investments.
Advamedica is a Delaware corporation involved in research, development, production, marketing, sale, distribution of hemostatic medical devices and related products and services in various countries in South-east Asia and India. JSA conducted legal due diligence on Advamedica’s wholly owned Indian subsidiary, Axio Biosolutions Private Limited and advised on documentation from an Indian law perspective. K&S Partners conducted the intellectual property diligence.
Advamedica’s investors include Accel, University of California and Ratan Tata’s UC-RNT and Chirate Ventures. The total deal value is reported to be USD 5,200,000.
JSA Team comprised – Partner – Archana Tewary and Associates – Medha Shah and Sanjna Vijh.
Archana has worked in private equity, capital markets and general corporate teams and has primarily worked on investments by private equity investors in unlisted companies and offerings of equities and securities by listed and unlisted companies.